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Abstract: Inflammatory bowel diseases (IBD) are a chronic inflammatory disorders with increasing
global incidence. Synbiotic, which is a two-point approach carrying probiotic and prebiotic
components in mitigating inflammation in IBD, is thought to be a pragmatic approach owing to the
synergistic outcomes. In this study, the impacts of dietary supplementation with probiotic Bacillus
coagulans MTCC5856 spores (B. coagulans) and prebiotic whole plant sugar cane fibre (PSCF) was
assessed using a murine model of IBD. Eight-week-old C57BL/6 mice were fed a normal chow
diet supplemented with either B. coagulans, PSCF or its synbiotic combination. After seven days of
supplementation, colitis was induced with dextran sulfate sodium (DSS) in drinking water for seven
days during the continuation of the supplemented diets. Synbiotic supplementation ameliorated
disease activity index and histological score (−72%, 7.38, respectively), more effectively than either
B. coagulans (−47%, 10.1) and PSCF (−53%, 13.0) alone. Synbiotic supplementation also significantly
(p < 0.0001) prevented the expression of tight junction proteins and modulated the altered serum IL-1β
(−40%), IL-10 (+26%), and C-reactive protein (CRP) (−39%) levels. Synbiotic supplementations also
raised the short-chain fatty acids (SCFA) profile more extensively compared to the unsupplemented
DSS-control. The synbiotic health outcome effect of the probiotic and prebiotic combinations may
be associated with a synergistic direct immune-regulating efficacy of the components, their ability
to protect epithelial integrity, stimulation of probiotic spores by the prebiotic fibre, and/or with
stimulation of greater levels of fermentation of fibres releasing SCFAs that mediate the reduction in
colonic inflammation. Our model findings suggest synbiotic supplementation should be tested in
clinical trials.
Keywords: synbiotic; prebiotic; probiotic; IBD; Bacillus spores; dietary fibre; sugar cane fibre;
ulcerative colitis
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1. Introduction
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition of the
gastrointestinal tract that comprises two partially overlapping but distinct clinical entities: Crohn’s
disease (CD) that involves the entire gastrointestinal tract and ulcerative colitis (UC) that is limited
to colon and rectum [1]. The incidence of CD and UC has become a global disease with accelerating
incidence in countries adopting a Westernised diet, highlighting the urgent need for research into
prevention and management of this complex and costly pathology [2]. Although the aetiology and
pathogenesis of IBD still remains unclear, emerging evidence supports the involvement of a recurrent
tripartite pathophysiological circuit encompassing gut dysbiosis, altered epithelial integrity and
defective immune responses [1]. Therefore, preventive and therapeutic approaches that impede or
break this inflammatory circuit by resolving one or more of the pathophysiological circuit components
are highly sought.
Dietary interventions are increasingly perceived as both preventive and corrective strategies to
normalise the dysfunctional microbiome, altered immune and barrier integrity functions to normality
in IBD [3–5]. In this regard, probiotic and prebiotic dietary fibres (DF) are thought to be useful in
mitigating the inflammatory circuit thereby resolving or preventing the severity of IBD. Both bioactive
ingredients can improve inflammatory parameters in the gut by modifying microbiota composition and
metabolites, regulating secretion of immunomodulatory molecules and protecting the colonic epithelial
barrier [1,6–8]. Synbiotics, being a combination of probiotic and prebiotic ingredients that positively
interact, potentially offer prophylactic and therapeutic effects that could function synergistically to
confer health benefits to the host.
DFs have shown particular promise in attenuating colonic inflammation in humans [9].
Meanwhile, the underlying mechanisms are likely to be multifactorial: they include dilution of toxins
via stool bulking and the production of metabolites, particularly short-chain fatty acids (SCFA),
as a result of microbial fermentation is frequently cited as a major potential contributor to the
protective effect [10]. DFs consist of edible plant parts that resist digestion and absorption in the
small intestine and undergo complete or partial fermentation in the colon. It is an extremely complex
group of substances, including non-starch polysaccharides, resistant starch, cellulose and hemicellulose,
oligosaccharides, pectins, gums, lignin, and waxes [11]. Much work on DFs, however, has examined
various purified ingredients that represent limited chemical complexity, contrasting to those that
naturally occur in fruits and vegetables [12]. Nevertheless, the biochemical complexity of DFs is
recently being more appreciated to be a vital factor influencing the gut microbial complexity [12–14].
This highlights the prudence of application of prebiotic fibres that are representative of whole plant
vegetables and fruits, prepared to retain fibre biochemical complexity. In this context, a process to
produce sugar cane fibre by wet diffusion to remove most of the sucrose from cut cane, which is then
dried and ground into a flour, has been reported to preserve the cell wall components and retain other
intrinsic nutritional biologically active components [15,16]. Such fibre, in addition to retaining other
micronutrients and polyphenols, also contains both soluble and insoluble benefits as well as rapid- and
poor-fermentable fibres and at ratios that more accurately represent natural whole plant foods. In a
recent study, such sugar cane fibre has been shown to impart positive effects on human gut microbiota
in vitro [17]. The high content of total dietary fibre (87%) was accounted for with respect to its positive
effect in this study. The relative similarity of this sugar cane fibre product to that in other whole plant
foods indicates its potential as a convenient supplementary source of dietary fibre that could alter
microbial ecology and have a positive influence for IBD attenuation.
Bacillus coagulans is a GRAS (generally recognised as safe) affirmed probiotic that can ferment a
variety of plant substrates rich in insoluble cell wall components [18,19] more efficiently than most
members of gut microbiota [20,21]. It is also known to be capable of modulating the innate immune
system by binding and interacting with the gastrointestinal tract epithelium [22,23]. This makes it
a suitable probiotic for its synbiotic combination with prebiotic whole plant sugar cane fibre (PSCF)
rich in insoluble cell wall fractions. Probiotic Bacillus coagulans MTCC (Microbial Type Culture
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Collection) 5856 spores in addition to exhibiting excellent immunomodulatory effects in vitro, have
shown significant survival during simulated gastric transit with substantial adhesion capacity to
human colonic epithelial cells [22]. Based on the aforementioned findings, we hypothesised that
preconditioning with probiotic B. coagulans MTCC 5856 spores, prebiotic PSCF and its synbiotic
combination might repress the onset and/or severity of DSS-induced colitis in mice. This study
aimed to evaluate the efficacy of probiotic B. coagulans spores and PSCF, both alone and in
combination as synbiotic to ameliorate the onset of experimental colitis in mice and further examine
its underlying mechanisms.
2. Materials and Methods
2.1. Probiotic Bacteria and Prebiotic Dietary Fibre
LactoSpore® (Sabinsa Corporation, East Windsor, NJ, USA) containing the probiotic strain Bacillus
coagulans MTCC 5856 (6 × 109 spores/gm) was produced by Sami Labs Limited (Bangalore, India) and
supplied by Sabinsa Corporation (Australia). Kfibre™, prebiotic whole plant sugar cane fibre (PSCF)
was supplied by KFSU Pty Ltd., Queensland, Australia.
2.2. Animals
Fifty C57BL/6J (seven week old) mice of both sexes of average weight 19g were obtained from the
University of Tasmania animal breeding facility and housed in a temperature-controlled environment
with a 12-h day/night light cycle. Individual body weights were assessed daily including over an initial
acclimation period of seven days. All mice had ad libitum access to radiation-sterilised rodent feed
pellets (Barastoc Rat and Mouse, Ridley AgProducts, Melbourne, Victoria, Australia) and autoclaved
tap water for drinking during experiments. All animal experiments were approved by the Animal
Ethics Committee of the University of Tasmania (ethics approval number: A0015840) and conducted
in accordance with the Australian Code of Practice for Care and Use of Animals for Scientific Purposes
(8th Edition, 2013). All efforts were made to minimize animals’ suffering and to reduce the number of
animals used.
2.3. Study Design and Treatments
Following one week of acclimation, mice at eight weeks of age were randomly allocated into
the following five groups (n = 10 per group): (1) Healthy control (HC), (2) DSS-control, (3) probiotic
B. coagulans MTCC 5856 spores (B. coagulans), (4) whole plant prebiotic sugar cane fibre (PSCF)
supplement, and (5) synbiotic combined supplement. Mice in HC and DSS-control groups received
4 g chow mash (standard chow pellet blended with water). The B. coagulans group received 4 g
chow mash supplemented with probiotic B. coagulans MTCC 5856 spores (2 × 109 CFU/day/mouse).
The PSCF group received 4g chow mash supplemented with Kfibre™ (200 mg/day/mouse). Synbiotic
treatment group mice received 4 g chow, each supplemented with B. coagulans MTCC 5856 spores
(2 × 109 CFU/ day/mouse) and Kfibre (200 mg/day/mouse). The chow mash was prepared fresh
each day. The mice were single-caged throughout the experiment to measure the defined daily intake
of respective treatments from prepared chow mash. The mice were fed these treatments for 14 days.
Colitis was induced during the last seven days of the experimental period as previously described [24],
by administering 2% dextran sulfate sodium (DSS; MP Biomedicals, colitis grade average molecular
weight: 36,000–50,000) in the drinking water of all groups except for the non-colitic DSS-control mice
which received normal drinking water. Mice were sacrificed on day 15 by CO2 asphyxiation.
2.4. Clinical Scoring and Histological Analysis
A Disease Activity Index (DAI) was determined daily in all mice by scoring for body weight,
hemocult reactivity or presence of gross blood and stool consistency during the week of DSS induction,
as detailed in [25]. Stool was collected from individual mice and tested for the presence of blood using
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Hemoccult II slides (Beckman Coulter Inc., Brea, CA, USA). Briefly, the following parameters were used
for calculation: (a) body weight loss (score 0 = 0%, score 1 = 1–5%, score 2 = 6–10%, score 3 = 11–15%); (b)
stool consistency (score 0 = normal, score 1 = soft but still formed, score 2 = very soft/loose stool, score
3 = diarrhoea/watery stool); and (c) blood in stool (score 0 = negative hemoccult, score 1 = positive
hemoccult, score 2 = Blood traces in stool visible, score 3 = rectal bleeding). DAI was determined
by combining the scores from these three categories. Body weights were measured for each animal
throughout the experiments and expressed as percent weight loss to the weight immediately before
DSS treatment. Fecal samples were collected and stored at −80 ◦C on day 14 for metabolite analysis.
After sacrificing the mice, the colons were removed from the caecum to the anus following the
method of Perera et al. [26]. The length of the colons from the ileocaecal junction to the rectum were
recorded. The colon was subsequently opened along its longitudinal axis and the luminal (mucosal)
contents were removed using sterilised 200 µL pipette tips prior to weighing the organ. The length and
weight of colon and spleen were documented. Spleen weight, colon length, and colon weight/body
weight ratio were calculated as macroscopic markers of inflammation. The mucosal and cecal contents
were collected for metabolite profiling and stored at −80 ◦C. The colon was bisected longitudinally,
and one half was prepared using the Swiss roll technique [27] whereas the remaining colonic tissue was
dissected out, segregated into proximal colon (PC) and distal colon (DC) and snap-frozen for molecular
analyses. Swiss rolls underwent 24 h fixation in 10% (v/v) neutral-buffered formalin. Swiss rolls were
subsequently transferred to 70% ethanol prior to progressive dehydration, clearing and infiltration
with HistoPrep paraffin wax (Fisher Scientific, Philadelphia, PA, USA). Swiss rolls were then embedded
in wax and 5 µm sections were cut using a rotary microtome. Sections were stained with haematoxylin
and eosin (H and E; HD Scientific, Sydney, Australia). Slides stained with H and E (n = 8 per
group) graded blindly for the severity of tissue damage at distal and proximal regions as described
previously [28,29]. Briefly, frequency of distribution of inflammation graded 0-3, crypt architectural
distortion and ulceration graded 0–5, tissue damage graded 0-3, inflammatory infiltrate graded 0–3,
goblet cell loss graded 0–3, mucosal thickening (oedema) were graded 0–3. All images were captured
on a Leica DM500 microscope using a Leica ICC50 W camera (Leica Microsys-tems, Wetzlar, Germany).
2.5. Alcian Blue Staining
DSS-induced alterations in goblet cells and subsequent depletion in synthesis and secretion of
mucin glycoprotein (MUC2) was analysed by Alcian blue staining (ab150662 Alcian Blue, pH 2.5
(Mucin Stain), Abcam, Australia) following the manufacturer’s instructions. Briefly, paraffin-embedded
colon sections (n = 4/group) were stained with Alcian blue, staining the acidic sulphated mucin blue
and the counterstained with Safranin O, staining the nuclei red following the method previously
described [30]. Computer-assisted image analysis was performed with a Leica DM500 microscope
(Leica Microsystems, Wet-zlar, Germany) and Leica ICC50 W camera (Leica Microsys-tems, Wetzlar,
Germany). The staining intensity (IOD) was assessed using Image Pro Plus 7.0 (Media Cybernetics,
Inc., Rockville, MD, USA) and used for comparison among groups [31].
2.6. Immunohistochemical Detection of Tight Junction Proteins
Immunohistochemical detection of epithelial tight junction (TJ) proteins was performed using
a Rabbit specific HRP/DAB (ABC) Detection IHC kit (ab64261, Abcam, Australia) following the
manufacturer’s instruction and as previously described [32]. Following removal of paraffin and
rehydration, the tissue sections were exposed to heat-induced epitope retrieval (4 min at 121 ◦C)
in a sodium citrate buffer, pH 6 in a Decloaking chamber (Biocare Medical, Pachico, CA, USA).
After washing the slides in 1× phosphate buffered saline (PBS) 2 mins/wash, endogenous peroxidase
activity was blocked by incubating the slides with hydrogen peroxide block for 10 min. Next, the slides
were washed with PBS (2 × 2 min) washes and protein block was then applied for 30 min at room
temperature to block non-specific background staining. Following PBS (1× 2 min) wash, colon sections
were then incubated with primary antibodies: anti-ZO-1 (NBP1-85046, Novus Biologicals, Australia,
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1:400); anti-occludin (NBP1-87402, Novus, 1:600); anti-claudin-1 (NBP1-77036, Novus, 1 µg/mL)
overnight at 4 ◦C. Sections were then washed with PBS (4 × 2 min) and biotinylated goat anti-rabbit
IgG was applied and incubated for 10 min at room temperature. At the end of incubation, the slides
were washed in PBS (4 × 2 min) and streptavidin peroxidase was applied to the sections and further
incubated for 10 at room temperature. The slides were then thoroughly rinsed with PBS (4 × 2 min)
before sections were covered with 3,3′-diaminobenzidine (DAB) chromogen and substrate solution for
10 min. Tissue sections were subsequently counterstained with hematoxylin, dehydrated, and mounted
with DPX media (Sigma-Aldrich, Sydney, Australia).
Computer-assisted image analysis was performed with a Leica DM500 microscope
(Leica Microsystems, Wet-zlar, Germany), Leica ICC50 W camera (Leica Microsys-tems, Wetzlar,
Germany), and Image Pro Plus 7.0 (Media Cybernetics, Inc., Rockville, MD, USA) software. The
expression of tight junction proteins (TJPs): ZO-1, occludin and claudin-1 was blindly assessed by
choosing random five fields on each slide (n = 4/group). Barrier TJ protein expressions and staining
intensity in colonic epithelium was expressed as the percentage expression of a respective TJ protein.
2.7. Myeloperoxidase Activity
The extent of the inflammatory cell invasion in the colon was examined by the assessment
of myeloperoxidase (MPO) activity [24]. Weighed and snap frozen PC and DC specimens (n = 3)
were analysed for MPO activity using a Myeloperoxidase Activity Assay kit (ab105136, colorimetric,
Abcam®, Cambridge, UK). Briefly, frozen tissue after washing in cold PBS, was resuspended in
MPO assay buffer, before homogenisation with 10–15 passes using an Omni TH tissue homogeniser
(Omni International, US) with 10–15 passes. The homogenate was then centrifuged at 13,000× g (10
min) and the supernatant assayed for MPO activity as per the manufacturer’s instructions. The values
are expressed as MPO activity units/g tissue.
2.8. Tissue Explant Culture and Cytokine Measurements
PC and DC colon tissues of mice from each group were cut, weighed and washed with cold
PBS before transferring to a 12 well plate containing 0.5 mL/well of RPMI1640 culture medium
(In Vitro Technologies Pty Ltd, Melbourne, Australia) supplemented with 10% v/v fetal calf serum
(Gibco, Life Technologies Pty Ltd, Melbourne, Australia), penicillin (100 mU/L), and streptomycin
(100 mg/L) (Sigma-Aldrich Pty Ltd, Sydney, Australia) as described previously [26]. After 24 h of
incubation, supernatant was collected from each well, centrifuged and stored at −80 ◦C until further
analysis. Serum was collected from blood drawn by cardiac puncture at the end of the study for
cytokine analysis.
The cytokine levels in colon tissue (n = 3) and serum (n = 3) were determined by immunoassay
using a Bio-Plex Pro Mouse cytokine 23-plex kit (Bio-Rad #M60009RDPD, Bio-Rad Laboratories,
Gladesville, NSW, Australia) following the manufacturer’s instructions and concentrations analysed
using a Bio-Plex 200 instrument (Bio-Rad) and Bioplex Manager software, version 6 (Bio-Rad
Laboratories) respectively. For tissues, the cytokine levels were normalized by dividing the cytokine
results (pg/mL) by the measured biopsy weight (g). The most significantly altered cytokines are
presented as pg/g of tissue.
2.9. iNOS Activity
The expression of inducible isoform of nitric oxide synthase (iNOS) in colonic epithelial cells in
response to pro-inflammatory stimuli [33] was determined in PC and DC specimens using a Nitic Oxide
Synthase Activity Assay kit (ab211084, Fluorometric, Abcam®, Cambridge, UK). Snap frozen proximal
and distal colonic tissues (n = 3) were washed in in cold PBS and resuspended in 200 µL NOS assay
buffer then homogenised by 10–15 passes of an Omni TH tissue homogeniser (Omni International,
Tulsa, OK, USA). The homogenate was then centrifuged at 10,000× g (10 min, 4 ◦C) and the supernatant
then underwent iNOS activity assay activity assay as per the manufacturer’s instructions. The amount
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of protein in the lysate was determined using DC™ Protein Assay (Bio-Rad Laboratories, Australia).
The results are expressed as iNOS activity mU/mg.
2.10. Serum C-Reactive Protein Analysis
The levels of C-reactive protein (CRP) in serum from respective groups (n = 3 samples/group)
were analysed using Mouse C-Reactive Protein/CRP Quantikine Elisa kit (MCRP00, R and D Systems,
Australia) following the manufacturer’s instructions. The results are expressed as µg/mL.
2.11. Volatile SCFA Analysis
Cecal, mucosal and fecal samples (n = 5 per group) were prepared and derivatized following
the protocol developed by Furuhashi et al. [34] with some modifications. Briefly, cecal, mucosal and
fecal samples of 100–150 mg fresh weight (stored at −80 ◦C) were weighed to ± 0.1 mg accuracy.
These samples were added to a sterile 1.5 mL bead-beating tube (NAVY Rino Lysis tubes, Next Advance,
Troy, NY, USA). A 1.0 mL aliquot isobutanol (10% MilliQ water), (LC-MS grade, Merck, Castle Hill,
NSW, Australia) was added to each sample, followed by two 30 s, 4000 rpm homogenization pulses
sandwiched between a 20-s pause interval (Precellys Evolution Homogenizer, Bertin Instruments,
Montigny-le-Bretonneux, France). The samples were subsequently centrifuged at 16,000× g for 6 min.
The supernatant (675 µL) was transferred to a clean round bottomed 2 mL centrifuge tube (Eppendorf
South Pacific Pty. Ltd., Macquarie Park, NSW, Australia) and NaOH (20 mM, 125 µL, Merck Pty Ltd.,
Castle Hill, NSW, Australia) and chloroform (400 µL, LC-MS grade, Merck Pty Ltd.,) were added.
The samples were briefly vortexed and centrifuged at 16,000·g for 3 min. The aqueous phase (upper layer,
400 µL) was transferred to a new clean round bottomed 2 mL centrifuge tube (Eppendorf South Pacific
Pty. Ltd., Macquarie Park, NSW, Australia) containing a boiling chip (Sigma Aldrich, Castle Hill, NSW,
Australia). Pyridine (100µL), isobutanol (80 µL) (both LC-MS grade, Sigma Aldrich, Castle Hill, NSW,
Australia), and MilliQ (Millipore Corporation) water (70 µL) were added and the samples were subjected
to gentle hand vortexing (swirling action) followed by the addition of 50 µL isobutyl chloroformate (98%
purity, Sigma Aldrich, Castle Hill, NSW, Australia). The tube was kept opened to release any generated
gases and was allowed to stand for about one minute. Hexane (150 µL, LC-MS grade, Sigma Aldrich,
Castle Hill, NSW, Australia) was then added to each tube, which was then capped and vortexed prior to
centrifugation at 15,700× g for 4 min. The upper phase (100 µL) was subsequently transferred to clean gas
chromatography (GC) autosampler vial fitted with silanized low volume glass inserts; Malathion (1 µL,
equivalent to 2.5 µg dry weight) was added as an internal standard.
The GC-MS analysis was performed on an Agilent 6890B GC oven coupled to a 5977B mass
spectrometer (MS) detector (Agilent Technologies, Mulgrave, VIC, Australia) fitted with an MPS
autosampler (Gerstel GmbH & Co.KG, Mülheim an der Ruhr, Germany). The GC oven was fitted
with two 15 m HP-5MS columns (0.25 mm ID and 0.25µm film thickness; 19091S-431 UI (Ultra Inert),
Agilent Technologies, VIC, Australia) coupled to each other through a purged ultimate union (PUU)
for the use of post-run backflushing. The sample (1.0 µL) was introduced via a multimode inlet
(MMI) operated in split mode (1:20). The column was maintained at 40 ◦C for 5 min, followed by
an increase to 250 ◦C at a rate of 10 ◦C/min. This was followed by a second increment to 310 ◦C at
a rate of 60 ◦C/min. The column was held at 310 ◦C for 1 min. The mass spectrometer was kept in
extractor ion mode (EI mode) at 70 eV. The GC-MS ion source temperature and transfer line were
kept at 250 ◦C and 280 ◦C, respectively. Detector voltage was kept at 1054 V. The MS detector was
turned off for the first 3 min and, at 4.0–4.8 min and 12.5–13.2-min time windows until the excess
derivatization reagent (chloroformate/hexane solvents) were eluted from the column. This ensured
that the source filament was not saturated and damaged. The scan range was kept in the range of
m/z 35–350 (35–350 Daltons). Data acquisition and spectral analysis were performed as described in
a previous study [35] and qualitative identification of metabolites was performed according to the
Metabolomics Standard Initiative (MSI) chemical analysis workgroup [36] using standard GC-MS
reference metabolite libraries (NIST 17, and an in-house CF-based metabolomics library developed
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after Smart et al. [37] with the use of Kovats retention indices based on a reference n-alkane standard
(C8-C40 Alkanes Calibration Standard, Sigma-Aldrich, Castle Hill, NSW, Australia).
2.12. Metabolic Phenotyping Analysis
Untargeted metabolomic profiling of cecal, mucosal and fecal samples (n = 5 per group) were
performed using GC-MS analysis as described previously [35].
2.13. Statistical Analysis
The samples in the study were randomly chosen for all the analysis to avoid bias. All data are
presented as means ± standard error of the mean (SEM). The statistical analysis was performed with
the use of GraphPad Prism Software (Version 7.0, San Diego, CA, USA) The data were evaluated using
One-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test to determine statistical
differences between the groups against the DSS-control samples. For the analysis of DAI and body
weight changes during the experimental period, two-way ANOVA followed by Tukey’s post-hoc test
was used, setting treatment and the time as the variables. A p-value of < 0.05 was considered significant.
3. Results
3.1. Effects of B. Coagulans, PSCF and Synbiotic Supplementation on DAI and Macroscopic Inflammatory
Markers in DSS-Induced Mice
In comparison with the HC group, the administration of probiotic, prebiotic and synbiotic
treatments in the respective groups did not show any sign of toxicity, which was evaluated by body
weight increase, food intake and general appearance of the animals. DAI (cumulative score for body
weight change, stool consistency and blood in feces) was evaluated to determine the efficacy of the
treatments in reducing the severity of disease symptoms in DSS-induced colitis (Figure 1A). Compared
with the DSS-control group that showed severe colitis symptoms, pre-conditioning with B. coagulans,
PSCF and synbiotic combination significantly reduced the DAI levels as early as day2 until the end
of experiment. At the end of the experiment, DAI of DSS-control group was significantly high (5.8 ±
0.5) (p ≤ 0.0001) compared with that of B. coagulans (3.1 ± 0.6, 47% reduction), PSCF (2.7 ± 0.5,
53% reduction), and synbiotic (1.6 ± 0.2, 72% reduction) groups. DSS induction in DSS-control mice
resulted in significant body weight loss until the end of experiment (−4.13 ± 1.4%). In contrast,
mice maintained healthy body weight gain with Bacillus (2.84 ± 1.7%), PSCF (4.25 ± 1.0%), and
synbiotic (4.7 ± 0.7%) treatments. Interestingly, PSCF was the more effective in reducing DAI starting
from day 2 of DSS and in remediating the body weight loss as early as day 5 owing mainly to the
impact of improvement in stool consistency on the DAI rating.
Nutrients 2019, 11, x FOR PEER REVIEW 7 of 24 
 
Untargeted metabolomic profiling of cecal, mucosal and fecal sa ples (n = 5 per group) ere 
performed using GC-MS analysis as described previously [35].  
2.13. Statistical Analysis 
The samples in the study were randomly chosen for all the analysis to avoid bias. All data are 
presented as means ± standard error of the ean (SE ). The statistical analysis as perfor ed with 
the use of GraphPad Prism Software (Version 7.0, San Diego, CA, USA) The data were evaluated 
using One-way analysis of variance (ANOVA) followed by Tukey’s post-hoc t st to determine 
statistical differences between the groups against the DSS-control samples. For the analysis of DAI 
and body weight chang s during the experimental period, two-way ANOVA followed by Tukey’  
post-hoc test was used, setting treatment and the time as the variables. A p-value of < 0.05 was 
considered significant.  
3. Results  
3.1. Effects of B. Coagulans, PSCF and Synbiotic Supplementation on DAI and Macroscopic Inflammatory 
Markers in DSS-I duced Mice 
In comparison with the HC group, the administration of probiotic, prebiotic and synbiotic 
treatments in the respective groups did not show any sign of toxicity, which was evaluated by body 
weight increase, food intake and general appearance of the animals. DAI (cumulative score for body 
weight change, stool consistency and blood in feces) was evaluated to determine the efficacy of the 
treatments in reducing the severity of disease symptoms in DSS-induced colitis (Figure 1A). 
ompared with the DSS-control group that showed severe colitis symptoms, pre-conditioning with 
B. coagula s, PSCF and synbiotic combination significantly reduced the DAI levels s early as day2 
until the end of experiment . At the end of the experiment, DAI of DSS-control gr up was significantly 
high (5.8 ± 0.5) (p ≤ 0.0001) compared with that of B. coagulans (3.1 ± 0.6, 47% reduction), PSCF (2.7 ± 
0.5, 53% reduction), and synbiotic (1.6 ± 0.2, 72% reduction) g oups. DSS induction in DSS-control 
mice resulted in significant body weight loss until the end of experiment (−4.13 ± 1 4%). In contr st, 
mice maintained healthy body weight gain with Bacillus (2.84 ± 1.7%), PSCF (4.25 ± 1.0%), and 
synbiotic (4.7 ± 0.7%) treatments. Interestingly, PSCF was the more effective in reducing DAI starting 
from day 2 of DSS and in remediating the body weight loss as early as day 5 owing mainly to the 
impact of improvement in stool consistency on the DAI rating. 
  
A B 
 1  2 3 4 5 6 7 8
0
1
2
3
4
5
6
7
8
Days on DSS
HC
DSS-control
B. coagulans 
 PSCF
Synbiotic
**
*** ***
*
** *
****
****
****
****
****
****
****
****
****
****
****
ns ns
ns
DA
I
****
 1  2 3 4 5 6 7 8
-8
-6
-4
-2
0
2
4
6
HC
DSS-control
B. coagulans 
 PSCF
Synbiotic
**** ****
****
****
****
********
% 
bo
dy
 w
eig
ht 
ch
an
ge
****
***
Days on DSS
Figure 1. Cont.
Nutrients 2019, 11, 818 7 of 24
Nutrients 2019, 11, x FOR PEER REVIEW 8 of 25 
 
  
C D 
 
 
E F 
Figure 1. Effect of B. coagulans spores, PSCF and synbiotic in DSS-induced colitis model. (A) Disease 
Activity Index (DAI), (B) % body weight change. Statistical significance among groups evaluated by 
two-way repeated-measures analysis of variance (ANOVA) followed by Tukey’s test. *p < 0.05, **p 
< 0.01, ***p < 0.001, ****p < 0.0001 vs. DSS-control group and data expressed as mean ± SEM (n =10 per 
group). Colon weight/body weight ratio (C), Spleen weight (D), Colon length (E) and Macroscopic 
appearance of colon (F). Data expressed as mean ± SEM (n =10 per group), evaluated by one-way 
ANOVA followed by Tukey’s Test. ns-non-significant, HC-Healthy control, PSCF-Prebiotic sugar 
cane fibre. 
The macroscopic evaluation of colonic segments determined the beneficial effects of all three 
treatments used in our study as evidenced by substantial reduction in colon weight/body weight ratio 
(B. coagulans, 7.68 ± 0.2; PSCF, 9.24 ± 0.3 and synbiotic, 8.74 ± 0.3 mg/g) compared with DSS-control 
group (11.12 ± 0.3 mg/gm) (Figure 1C). Intestinal inflammation is associated with spleen enlargement 
[24] and, as expected, relative spleen weight of untreated DSS-control mice was significantly higher 
(0.076 ± 0.004 g) than that of HC mice (0.054 ± 0.003 g). PSCF (0.062 ± 0.003 g) and synbiotic (0.063 ± 
0.002 g) were equally significantly effective in reducing spleen weight while B. coagulans did not 
affect the relative spleen weight (Figure 1D). In contrast to shortening of colon length (Figure 1E,F) 
in DSS-control group (6.75 ± 0.3 cm), synbiotic treatment proved effective in reducing this outcome 
by maintaining the colon length (8.12 ± 0.2 cm), significantly equal (p = 0.99) to that of HC group (8.01 
± 0.2 cm). These markers are considered to be directly correlated to the severity of colonic damage in 
this experimental model of colitis [24].  
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l n (F). Data expre sed as mean ± SEM (n =10 per group), evaluated by one-way
f ll ’s Test. ns-non-significant, HC-Healthy control, PSCF-Prebiotic sugar
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i l ation of colonic segments determined the beneficial effects of all three
tre t in our study as evidenced by ubst ntial reduction in colon weight/body weight
ratio (B. coagulans, 7.68 ± 0.2; PSCF, 9.24 ± 0.3 and synbiotic, 8.74 ± 0.3 mg/g) compared with
DSS-control group (11.12 ± 0.3 mg/gm) (Figure 1C). Intestinal inflammation is associated with
spleen enlargement [24] and, as expected, relative spleen weight of untreated DSS-control mice was
significantly higher (0.076 ± 0.004 g) than that of HC mice (0.054 0.003 g). PSCF (0.062 ± 0.003 g)
and synbiotic (0.063 ± 0.002 g) were equally significantly effective in reducing spleen weight while
B. coagulans did not affect the relative spleen weight (Figure 1D). In contrast to shortening of colon
length (Figure 1E,F) in DSS-control group (6.75 ± 0.3 cm), synbiotic treatment proved effective in
reducing this outcome by maintaining the colon length (8.12 ± 0.2 cm), significantly equal (p = 0.99) to
that of HC group (8.01 ± 0.2 cm). These markers are considered to be directly correlated to the severity
of colonic damage in this experimental model of colitis [24].
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3.2. Effects of B. Coagulans, PSCF and Synbiotic Supplementation on Histological Alterations in
DSS-Induced Mice
Histological (H and E staining) examination of proximal colon (PC) and distal colon (DC) sections
of DSS-induced mice showed altered erosion or destruction of epithelium, crypt distortion, depletion
of goblet cells, submucosal oedema, and inflammatory cellular infiltration in the colon, mostly affecting
the DC (Figure 2A). HC mice showed no signs of histological colon damage with score 0, while DSS
induction in DSS-control mice resulted in a cumulative damage score of 10.5 ± 0.8 for the PC and
17.4 ± 0.5 for the DC (Figure 2B). Supplementation of DSS-induced mice with B. coagulans, PSCF and
synbiotic induced protection and repair of the colonic mucosa. B. coagulans and synbiotic in particular
were more effective in retention of colonic structure, protection of crypts and goblet cells and rescued
infiltration of inflammatory cells, which resulted in a significant overall reduction of cumulative
histological score of DC (10.1 ± 1.2 and 7.38 ± 0.7 respectively). Relatively, PSCF also provided partial
significant protection with histological score of 13.0 ± 1.0. In contrast, PCSF had no effect in PC
(10.1 ± 0.5) with only B. coagulans and synbiotic treatments being significantly successful in reducing
damage to the PC with histological scores of 9.5 ± 0.7 and 7.8 ± 0.3 respectively. Unlike DSS-control
group, there was reduced polymorphic inflammatory infiltrate in the lamina propria and submucosa
in probiotic, prebiotic and synbiotic supplemented group. This observation corroborates with the
significantly reduced MPO activity in the colon (Figure 2C) of all three treatments compared with the
DSS-control group. The attenuation of colonic inflammation in pre-conditioned mice (B. coagulans,
PSCF and synbiotic) is probably due to the anti-inflammatory properties of the functional dietary
ingredients tested in this study.
3.3. Effects of B. Coagulans, PSCF and Synbiotic Supplementation on Goblet Cells and Colonic Tight
Junction Barrier
Histological examination of distal colon from DSS mice showed a depletion of goblet cells
when compared to HC and pre-conditioned mice. This suggested beneficial effects of probiotic and
prebiotic ingredients on the intestinal epithelium potentially through stimulating mucus secretion
by goblet cells. Specific staining with Alcian blue was therefore carried out to assess the mucus
production following the administration of probiotic, prebiotic and synbiotic treatments. As depicted
in Figure 3, in comparison with DSS-control group, there was a higher level of mucus staining with
Alcian blue in supplemented mice samples. This implied that there has been an induction of higher
levels of mucus secretion in the DSS-challenged mice that received B. coagulans spores, symbiotic,
and PSCF supplementaions. Unlike the DSS-controlled samples where, goblet cells were almost entirely
destroyed, the mice supplemented with synbiotic and B. coagulans showed protection of the goblet
cells. PSCF also partially protected the goblet cells with mucus staining compared with DSS-control.
Immunohistochemical analysis was then performed to evaluate the assembly of the TJs and the
integrity of the intestinal barrier. The presence of the TJ proteins-ZO-1, occludin, and claudin-1 on
the tissue sections were analysed (Figure 4). In HC, ZO-1 (Figure 4A) staining was more intense in
the apical tight junction complex both at the surface and in the crypts. In addition to showing their
presence at the crypt surface, occludin (Figure 4B), and claudin-1 (Figure 4C) proteins stained more
strongly at the basolateral membrane of crypts. As previously reported [38,39] such signals were weak
or totally absent on the epithelium of DSS-control sections resulting in very low percentage TJ protein
expressions. Basolateral and partial apical staining of ZO-1, occludin and claudin-1 was maintained
with B. coagulans and synbiotic supplementation in DSS-treated animals. While PSCF was able to
partially maintain ZO-1 and claudin-1 staining, such an effect was less evident for occludin. Synbiotic
treatment was most effective in preserving the TJ protein expressions in DSS-induced mice further
confirming its beneficial effects on the intestinal integrity.
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i r . coagulans spores, PSCF and synbiotic treatments on DSS-induced colon injury and
i flamm tion. (A) Histological images of proximal and distal colonic tissues stained with hematoxylin
and e sin at 20× f r each experimental group. (B) Histological score cal u ated after microscopic
analy es of proximal and distal section of the c lon. (C) Myeloperoxidase (MPO) activity in colonic
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group is illustrated in the graph. Results expressed as mean ± SEM (n = 4 per group), evaluated by 
one-way ANOVA followed by Tukey’s test (*p < 0.05, ***p < 0.001). 
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Figure 3. Effect of B. coagulans spores, PSCF and synbiotic on goblet ce ls. The paraffin embe ded
sections were stained ith lci i goblet cel s and in production of mucus in
distal col nic tissue in each exp rimental group (40×) and staining i tensity (IOD) of respective group
is illustrated in the graph. Results xpressed a mean ± SEM (n = 4 per group), evaluat d by one-way
ANOVA followed by Tukey’s test (*p < 0.05, ***p < 0.001).
Nutrients 2019, 11, 818 11 of 24
Nutrients 2019, 11, x FOR PEER REVIEW 12 of 25 
 
 
Figure 4. Effects of B. coagulans spores, PSCF and synbiotic on expression of epithelial tight junction 
proteins. Immunohistochemical detection of (A) ZO-1, (B) Occludin and (C) claudin-1 and its 
respective percentage of expression in colon at 40×. Data expressed as mean ± SEM (n = 4 per group) 
and statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test *p 
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. DSS-control group. 
 
Figure 4. Effects of B. coagulans spores, PSCF and synbiotic on expression of epithelial tight junction
proteins. Immunohisto hemical detection of (A) ZO-1, (B) O cludin and (C) claudin-1 and its respe tive
erc ntage of expres i n in colon at 40×. Data expressed as mean ± SEM (n = 4 per group) and
statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 vs. DSS-control group.
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3.4. Immunomodulatory Effects of B. Coagulans, PSCF, and Synbiotic Supplementation on Immune Markers in
DSS-Induced Mice
The cytokine analysis of the colonic segments and serum measured the intestinal
immunomodulatory and anti-inflammatory effects of B. coagulans, PSCF and their synbiotic
combination. A beneficial impact of ameliorating the altered immune response induced by DSS
intake was noted. Overall, probiotic, prebiotic, and synbiotic treatments remarkably reduced the
pro-inflammatory cytokine secretions of IL-1α, IL-1β, IL-6, IL-12, TNF-α, and IFN-γ in proximal
and distal colon segments compared with that of the DSS-colitic segments (Figure 5), while no
significant effect of supplementations was noted on other cytokine levels (Supplementary Figure
S1). B. coagulans and synbiotic treatments were equally effective in maintaining the levels of these
altered cytokines relative to that of non-colitic mice while PSCF did not show significant effective
reduction of IL-12 cytokine levels (Figure 5D). Synbiotic treatment was statistically more potent in
suppressing the elevated levels of IL-1α (−90.29%) and IL-12 (−67.42%) compared with B. coagulans
(−85.94%, −52.20%, respectively) in the DC. No positive effect was observed in the PC segment for
IL-6 and TNF-α levels by PSCF treatment. However, the excellent immunomodulatory effect in the
DC for respective cytokines was confirmed (Figure 5C,E), implicating its differential effects in these
colonic segments.
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Figure 5. Effect of B. coagulans spores, PSCF and synbiotic on immune markers in colon tis ues and
blood serum. Protein levels of cytokines including (A) IL-1α, (B) IL-1β, ( ) I -6, ( ) I -12, ( ) - ,
(F) IFN-γ in proximal and distal colon explants as well as cytokine l v ls of (G) IL-1β, (H) IL-10, and (I)
IL-12 in blood serum were analysed by Bio-plex. iNOS activity n colon tissues (J) measured by NOS
activity assa and CRP levels in serum (K) by ELISA. Statistical signifi nce among groups evaluated
by one-way ANOVA followed by Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.00 1 vs.
DSS-colitic group and data expr ssed as mean ± SEM (n = 3 per group).
Si ilar i uno l t r effects ere foun on the serum cytokines Il-1β, IL-12, and IL-10
(Figure 5G–I), while no significant effect was observed for other serum cytokines (Supple entary
Figure S1). ll t ree treat e ts s st ti ll rest re t e I - le els t l es si il r t ice,
while synbiotic treat ent was significantly more efficacious in reducing pro-inflammatory IL-1β
levels in serum. Moreover, B. coagulans and synbiotic treatments increased the anti-inflammatory
IL-10 levels in serum (181.2 ± 8.70, 184.7 ± 3.81 pg/mL respectively) compared with the DSS-colitic
group (143.8 ± 12.80 pg/mL) (Figure 3H). iNOS activity which is known to be high in colitis in
response to pro-inflammatory stimuli [33], was significantly suppressed in both colon segments by all
treatments (Figure 5J) compared with DSS-colitic levels. Serum CRP level was significantly higher in
the DSS-control group (14.58 ± 0.45 µg/mL) in comparison with HC animals (9.32 ± 0.45 µg/mL).
Bacillus, PSCF and synbiotic remarkably normalised the CRP levels (9.67± 0.34, 9.95± 0.65, 8.83± 0.59
µg/mL, respectively) to that of the HC group. These results confirmed the notable anti-inflammatory
efficacy of probiotic Bacillus spores, prebiotic PSCF and synbiotic treatments used in our study.
3.5. Effects of B. coagulans, PSCF and Synbiotic Supplementation on Altered Fecal Metabolic Profile in
DSS-Induced Mice
Fecal metabolites were analysed using GC-MS to gain an overview of changes induced by
B. coagulans, PSCF and synbiotic supplementation in DSS-treated mice. A total of 61 metabolites of
different functional groups such as sugars, amino acids, volatile fatty acids, and biogenic amines
were detected. A supervised partial least squares-discriminant analysis (PLS-DA) was performed
to evaluate metabolic phenotyping of each experimental group as shown in Figure 6A. The samples
from HC and DSS-control clusters were clearly divergent indicating marked distinction in metabolic
patterns between the two groups. While, clusters of supplemented mice samples overlapped with
that of HC and DSS-control, clear demarcation of the synbiotic and B. coagulans cluster was noted,
with PSCF showing only partial divergence relative to that of DSS-control. This indicates substantial
efficacy of B. coagulans to metabolise PSCF that, in turn, induced significant biochemical changes
potentially owing to their synergistic effects as evidenced from synbiotic samples. Combination of
PLS-DA (R2Y = 0.810 (p = 0.01), Q2 = 0.710), VIP scores (Figure 6B) and significance analysis for
microarrays (SAM) enabled us to identify potential biomarkers. The results showed 61 metabolites
with 40 statistically significant compounds contributing to the clustering, with their SAM scores fold
changes and International Chemical Identifiers (InChI) and standard InChI hashes (InChIKey IDs)
listed in Table S1. Key metabolic markers making a significant contribution were identified by VIP
analysis as displayed in Figure 6B. Among these identified metabolites, noticeable differences between
Nutrients 2019, 11, 818 14 of 24
DSS-control, and HC samples were noted particularly for succinic acid, stearic acid, and glycerol.
Synbiotic supplementation was beneficial in minimising the metabolite alterations induced by DSS
(Figure 6B and Table S1).
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3.6. Effects of B. Coagulans, PSCF and Synbiotic Supplementation SCFA Levels in DSS-Induced ice
As shown in Figure 7, supplementation of DSS-induced mice with B. coagulans, PSCF, and synbiotic
treatments induced substantial modulations in the SCFA concentrations and their effects varied across
cecal, luminal and fecal contents. Overall, the highest concentration of SCFA were noted in cecal
contents compared to mucosal and fecal contents. There were no significant differences between
the concentration of acetate and propionate in DSS-control and HC mice. PSCF however, induced
a significant increase in the acetate levels in cecal and mucosal samples while, Synbiotic treatment
was most significant in elevating acetate concentrations in mucosal-associated samples. All three
supplementations were significantly effective in improving the propionate concentrations in cecal and
mucosal contents while, only synbiotic supplementation increased propionate levels in fecal samples.
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Figure 7. Effects of B. coagulans spores, PSCF and synbiotic in modulating SCFA concentrations in
cecal, mucosal-associated and fecal contents in DSS-induced colitis. Cecal- acetate (a), proionate (d),
butyrate (g), valerate (j), succinate (m); mucosal-associated acetate (b), proionate (e), butyrate (h),
valerate (k), succinate (n) and fecal- acetate (c), pr pionate (f), butyrate (i), valerate (l), succinate
(o). -Statistical significance among groups evaluated by one-way ANOVA followed by Tukey’s test.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. DSS-colitic group and data expressed as mean ± SEM
(n = 5 per group). ns-non-significant
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Butyrate levels were significantly decreased by DSS administration (2.05 ± 0.6 µg/g) compared
with that of HC mice (7.91 ± 1.1 µg/g) in the cecum. The decrease in butyrate induced by DSS was
maintained at control levels with all three supplements in the cecum with PSCF (13.2 ± 2.4 µg/g)
being significantly more effective than B. coagulans (11 ± 0.9 µg/g) and synbiotic (10.4 ± 1.0 µg/g).
Similarly, in fecal content, PSCF significantly improved butyrate (13.6 ± 1.6 µg/g compared with
3.72 ± 0.1 µg/g for DSS-colitic followed by synbiotic (8.15 ± 0.6 µg/g) while B. coagulans (6.69 ± 0.1
µg/g) had no effect. Synbiotic supplementation resulted in marked increase in mucosal-assocaited
valerate while, PSCF caused elevation in its concentration in fecal content. Similarly, synbiotic was
more efficient in reducing elevated succinate levels.
4. Discussion
Dietary strategies involving probiotic and prebiotic fibre components that function by modulating
immune responses, colonic epithelial integrity and microbial composition and related metabolites are
being widely investigated for the prevention or reduction of severity of IBD [40,41]. The present study
clearly supported the premise that conditioning of the gut with synbiotic supplementation containing
compatible probiotic and prebiotic fibre can be greatly beneficial to reducing the symptoms and severity
of DSS-induced acute colitis in mice. The observations confirmed substantial anti-inflammatory
efficacy by synbiotic supplementation containing B. coagulans and PSCF. This was evidenced by the
improvement of clinical symptoms, macroscopic, histological, biochemical, metabolic and immune
parameters in the DSS-induced colitic mice model.
The addition of 2% (w/v) DSS to drinking water for seven days without ameliorating treatments
resulted in a progressive rise in DAI (Figure 1A), owing to both body weight loss (Figure 1B) and
excretion of diarrheic/bleeding feces. However, the supplementation of DSS-induced mice with
B. coagulans, PSCF, and their synbiotic combination significantly attenuated the severity of the DSS
damage and improved DAI and macroscopic markers of inflammation (Figure 1C–F). The ability of
PSCF to show early effect on DAI and body weight could be related to its high content of insoluble
hemicellulose. This fraction has a large water-holding capacity thus, could appropriately contribute
to regulating the fecal water content in colitic mice [42,43]. The anti-diarrheal effect of B. coagulans
have been previously confirmed [44]. The increased beneficial effects of synbiotic supplementation
in reducing the disease severity could be related to the synergistic actions between the probiotic and
prebiotic components.
A potentiated synbiotic effect relative to that of B. coagulans and PSCF individually was also
evident from the histology of the colon compared with DSS-control mice (Figure 2A,B). Synbiotic
supplementation showed substantial protection to the colonic epithelial architecture by mitigating
crypt disruption, loss of goblet cells, submucosal edema and epithelial structure damage induced by
DSS. Synbiotic supplementation also induced suppression of infiltration of activated neutrophils as
evidenced by significant reduction in MPO activity in DSS-induced mice (Figure 2C). The infiltration
of activated neutrophils is one of the most prominent histological features observed in IBD and is
directly proportional to the MPO activity. Superoxide anions and other reactive species produced
by neutrophils leads to tissue necrosis and mucosal dysfunction in IBD [39]. The reduction in MPO
activity suggests that synbiotic supplementation imparted an anti-inflammatory effect, in addition to
histological protection.
Disruption of intestinal epithelial TJs and impaired epithelial barrier function is a central event
in the pathogenesis of IBD and may lead to persistent aberrant immune reactions, thus accelerating
gut inflammation and the inflammatory circuit [45]. Synbiotic treatment in our study was the most
effective followed by B. coagulans and PSCF in protecting the expression level of TJ proteins (ZO-1,
occludin and claudin-1) in DSS-induced mice (Figure 4). TJs create a semi-permeable barrier against
paracellular penetration of harmful substances from the gut lumen [45]. Bacillus subtilis intake has
been recently confirmed to upregulate the expressions of TJ proteins for improved barrier function
in colitic mice [46] and corroborates with our results. Moreover, synbiotic and B. coagulans protected
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the goblet cells and mucin production more effectively than PSCF alone (Figure 3). This indicates the
possible ability of these B. coagulans MTCC 5856 spores to benefit goblet cell structure and function
and needs further investigation to determine the mechanism of this effect. Some Bacillus species have
been shown to upregulate mucin glycoproteins and protect colonic mucus layer integrity and goblet
cell function [47]. Although we could not confirm if synbiotic supplementation had a stimulating
effect on TJ proteins and/or localisation or, instead if it avoided TJ degradation by DSS, we observed
that synbiotic supplementation significantly maintained the TJ patterns similar to that of animals
in HC. This is indicative that synbiotic supplementation significantly preserved the integrity of the
epithelium. The synergy between B. coagulans and PSCF could have imparted excellent protection
and/or maintenance of epithelial integrity on DSS-induced mice, thus supporting its application in
IBD to reinforce intestinal barrier integrity.
Alterations in the barrier integrity in IBD also leads to aberrant immune responses resulting in
an inflammation cascade and tissue damage [48]. Although B. coagulans and PSCF supplementations
alone were able to modulate the tested cytokines (IL-1α, IL-1β, IL-6, IL-12, TNF-α, and IFN-γ), a more
profound anti-inflammatory effect was observed with synbiotic supplementation in both the colon and
serum (Figure 5A–I). A spike in the levels of IL-1β, IL-6, and TNF-α have been implicated in human
IBD pathogenesis [49]. Such pro-inflammatory cytokines are secreted at high levels by activated lamina
propria antigen presenting cells in response to inflammation. Pro-inflammatory cytokines such as IL-6,
TNF-α, and IL-1β are being targeted by therapeutic approaches to curb the aberrant inflammatory
response in IBD due to their roles in the pathogenesis of the disease [50–52]. TNF-α is reported to exert
its pro-inflammatory effect through elevated production of IL-6 and IL-1β [53]. This is in line with
the present study, where DSS-induction caused elevated secretions of these cytokines in DSS-control
group relative to that of HC (Figure 5). Upregulation of pro-inflammatory cytokine levels has also
been reported to upregulate iNOS expression and secretion of nitric oxide that causes tissue damage in
IBD [54]. The anti-inflammatory effects of synbiotic, B. coagulans and PSCF in suppressing the levels
of these pro-inflammatory cytokines as well as reducing iNOS activity in colonic tissues, indicates
their immunomodulatory potentials. B. coagulans MTCC 5856 spores in our previous study showed
excellent immunomodulatory effect in vitro [22]. Marked reduction in pro-inflammatory cytokines in
the colon of DSS-induced mice in the current study further supports its excellent immunomodulatory
efficacy in IBD application.
Synbiotic supplementation was the most effective in demonstrating noticeable anti-inflammatory
effect by significantly reducing the serum levels of pro-inflammatory IL-1β and IL-12 while
concurrently elevating anti-inflammatory IL-10 in the serum. IL-10 plays a prominent role in
counterbalancing Th1 and Th17 immune activity in IBD towards a Th2 response by downregulating
antigen presentation and subsequent release of proinflammatory cytokines thereby attenuating
mucosal inflammation [53]. IL-10 has been reported to play a role in maintaining intestinal
barrier integrity possibly owing to effects on zonulin pathway [55]. The ability of B. coagulans
spores to elicit IL-10 levels in inflammatory condition has been determined in vitro and in human
subjects. Thus, the anti-inflammatory efficacy of synbiotic supplementation could be related to major
immune-regulating capability of B. coagulans MTCC 5856 spores, thereby supporting its application
in synbiotic therapies for IBD. Furthermore, synbiotic treatment also reduced the increased CRP
levels in the serum of DSS-induced mice. In the inflammatory state, circulating IL-6 promotes CRP
production in the liver and its release into the bloodstream [56]. Elevated levels of CRP has been
implicated in human IBD patients [57]. The reduction in overall pro-inflammatory mediators by
synbiotic supplementation may be due to either direct immune-regulating effect of the B. coagulans and
PSCF on cytokine secretion or it could be owing to their indirect effect on the protection of intestinal
barrier integrity. In either case this leads to reduction in luminal antigens and full activation of the
innate immune system.
DNA extracted from cecal, fecal and mucosal-associated contents from DSS-induced mice in
the present study, failed amplification before 16s rRNA sequencing owing to the presence of DSS
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in the samples that inhibited the PCR amplification as known earlier [58]. The microbiota profiling
of DSS samples could therefore not be performed and is the limitation of the study. The levels
of microbiota-derived untargeted metabolites and SCFAs were therefore alternatively analysed as
signatures of the gut microbiota that contribute to modulating the immune activity of the intestinal
mucosa [59,60]. The untreated DSS-control mice exhibited distinct fecal metabolic phenotype relative
to that of HC. This was reflective of clinical and animal IBD studies that confirmed significant
differences in metabolic profiles between healthy and IBD patients [61–63]. The metabolic analysis
of supplemented mice in our study resulted in considerable normalization of metabolic profile
indicating the positive effects of synergistic combination of B. coagulans and PSCF that induced
marked improvement in metabolic pattern. Notably for mice supplemented with PSCF there was
not much distinction from the DSS-control group was observed but the synbiotic combination with
B. coagulans resulted in an improved metabolic pattern. This marked synergism could be associated
with the acceleration of fermentation of insoluble plant cellular materials, such as hemicellulose in
PSCF, by the supplemented B. coagulans [18]. The resulting higher levels of fermentation metabolites
would thus, in turn, influence other beneficial microbial metabolic activities. This further supports
the application of compatible synbiotic components to generate maximum benefits through increased
SCFA production.
Increased levels of microbiota-derived SCFAs are inversely associated with dysbiosis in IBD [64].
Of particular interest are higher levels of acetate, propionate and butyrate, which results from
fermentation of indigestible carbohydrates from fibre-rich diets. The effects of SCFAs have been
studied to in animal models of colitis [42] and clinical UC [65]. Each type of SCFA is likely to contribute
to host health [66]. In this study we determined the SCFA profile along the gastro-intestinal tract,
analyzing samples across cecal, mucosal-associated, and fecal contents. The concentration of SCFAs
varied along the length of the gut, with most abundant levels in the cecum and PC, while it declined
towards the DC [66]. In line with a recent study [67], cecum showed the highest levels of all the
SCFAs tested in our study irrespective of the supplementation. Cecum is considered the major site
for fermentation in the rodent gut and contains the largest pool of microbiota. It therefore generates
the most SCFAs. However, some recent studies have also reported changes in the microbiota and
associated amounts of metabolites in along different regions of gastro-intestinal (GI) tract [67–69].
Therefore, the overall GI profile is of importance when associating the gut microbiome and metabolites
with health outcomes.
All three supplementations caused a substantial increase in concentrations of measured SCFAs
compares with that of DSS-control group. However, the potentiated effect of synbiotic supplementation
is evidenced by induction of SCFA production along the entire length of the colon compared to
B. coagulans supplementation alone where the additional SCFA production capacity was absent past
the cecum. This effect highlights the advantage of using a compatible prebiotic fibre as synbiotic
companion with a particular probiotic that can metabolize it. The high total dietary fibre content of
PSCF (87%) [17] would contribute to this effect. PSCF supplementation resulted in increased butyrate
levels line with an in-vitro study with human gut microbiota utilizing sugar cane fibre [17]. The effect
of additional SCFA production in cecum by B. coagulans would not extend to the proximal or distal
parts of the colon. In the current study, the elicited extra SCFAs with synbiotic supplementation from
cecum to the fecal pellets indicated the ability of B. coagulans to utilize the PSCF to also generate SCFAs
after the cecum. The ability of B. coagulans to metabolize a variety of plant fibers for fermentation,
including cranberry fibre [70] and fenugreek seeds [71], to produce SCFAs and hemicellulose [18] for
lactic acid production has been previously determined.
PSCF supplementation also resulted in increased butyrate levels, correlating with results of an
in-vitro study with human gut microbiota utilizing sugar cane fibre [17]. This ability of synbiotic
supplementation for eliciting butyrate levels along the entire length of colon could contribute to the
beneficial effect observed in the current study. Butyrate is the preferred energy source for colonocytes
and has the ability to regulate cytokines thus showing protection against inflammation in UC and
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colorectal cancer [66]. Butyrate has been demonstrated in in vitro [72,73] and in vivo [74] studies
to increase epithelial integrity and mucus secretion, consistent with the immunohistological and
mucus staining analysis in the present study. The substantial increase in butyrate levels in the
cecum by B. coagulans supplementation may be due to ability to support the growth and activity of
butyrate producers probably via cross-feeding of the lactic acid production. B. coagulans are known
to be efficient at producing lactic acid through fermentation of various plant substrates, including
hemicellulose [18,19]. Lactic acid is reported to be utilized by strictly anaerobic butyrate-producing
bacteria of clostridial clusters XIVa for the production of high concentrations of butyric acid [75]. Thus,
the synbiotic approach with probiotic bacteria and prebiotic fibre that directly or indirectly influence
butyrate production may help to restore intestinal barrier integrity in diseased state. This effect was
evidenced by the significant reduction in DSS-induced colonic epithelial damage (Figure 2) by synbiotic
supplementation in our study.
Acetate and propionate have also been studied to benefit epithelial integrity via binding with
certain metabolite-sensing G-protein-coupled receptors (such as GPR43, GPR109A) and modulating
immune response [76–78]. Valerate that has been determined to stimulate intestinal growth and
attenuate inflammatory pathogenesis in colitis and cancer to metabolic disorders [79] was increased
by synbiotic supplementation. Besides its positive effect in colon, SCFAs have also been exhibited
to mediate improved host metabolism and modulate the activity of the enteric nervous system [66],
thus providing benefits beyond GI tract. The high levels of immuno-modulatory effects observed
in the present study could also possibly be correlated to high SCFA levels induced by synbiotic
supplementation owing to the synergistic combination. SCFAs by engaging with engage with GPRs
are known to induce immune-modulation leading to a direct local and systemic anti-inflammatory
effects [76,80]. This further supports the application of synergistic synbiotic combinations to achieve
maximum benefits in resolving the inflammatory circuit in IBD.
5. Conclusions
This is a detailed study highlighting the site-specific inflammatory and SCFA changes in a mice
model of IBD as a result of synbiotic supplementation of the normal diet with prebiotic whole plant fibre
and probiotic spores. The synbiotic pre-supplementation resulted in a substantial anti-inflammatory
effect, reducing disease severity, colonic damage, and inflammatory mediators while modulating the
metabolite and SCFA profiles of DSS-induced gut damage. The research has clearly demonstrated that
the supplementation of whole plant PSCF and B. coagulans spores produced a synergistic combination
that protected mice against acute damage induced by DSS in mice. The results underscore the
significant efficacy of synbiotic applications to increase the beneficial and preventive effects on the host
by targeting different mechanistic approaches to resolve inflammation cycle. However, the differences
in the evolved biology of humans compared to mice requires caution in translation of the results
to impacts on human disease [81]. While mice models do allow the changes in gut microbiota, as a
result of pre- and probiotic combinations to be studied in a controlled experiment direct human trials
will be needed. The delineation of the synergistic biological actions of probiotic B. coagulans spores
and prebiotic PSCF in mouse model of IBD provides support for investigating their therapeutic and
preventive effects in human IBD. However, the ability to reduce the severity of DSS-induced colitis
was demonstrated using pre-supplementation. Human trials should be aimed at proactive prevention
or after partial control of inflammatory disease, such as in association with drug treatment.
Patents: The information from this study has been filed as a provisional patent application in
Australia titled “Preparation for the Treatment of Inflammatory Bowel Disease using a Whole Plant
Fibre Extract from Sugar Cane” with application number 2018902145 and a filing date of 15 June 2018.
Information relating to novelty of synergy between probiotic Bacillus coagulans and prebiotic whole
plant sugar cane fibre in imparting health benefits is the subject of the patented claim.
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